IMMATICS N V
Immatics NV (IMTX) is a clinical‑stage immuno‑oncology company developing T‑cell receptor (TCR)‑based therapies and engineered T‑cell engager programmes for solid tumours. Its science focuses on identifying tumour-specific antigens and creating therapies that direct the immune system to those targets. As a clinical‑stage biotech with a market capitalisation of roughly $1.28B, value is driven mainly by trial outcomes, regulatory decisions and partnerships rather than steady revenue. That profile brings upside if trials succeed, but also considerable risk: clinical setbacks, regulatory delays and the need for further funding are common. This summary is educational only, not investment advice; investors should assess their own risk tolerance, seek diversified exposure and consider consulting a financial adviser before making decisions.
Stock Performance Snapshot
Analyst Rating
Analysts strongly recommend buying Immatics NV's stock, believing its price could significantly rise.
Financial Health
Immatics NV shows stable revenue and cash flow, but its overall financial indicators are moderate.
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Discover More Opportunities
ACADIA PHARMACEUTICALS INC
ACADIA Pharmaceuticals Inc. is a biopharmaceutical company focused on the development and commercialization of treatments for central nervous system disorders.
ADAPTIVE BIOTECHNOLOGIES CORP
Adaptive Biotechnologies Corporation is a commercial-stage biotechnology company. The Company is focused on harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its immune medicine platform reveals and translates the massive genetics of the adaptive immune system with scale, precision and speed. It applies its platform to partner with biopharmaceutical companies, inform drug development, and develop clinical diagnostics across its two business segments: Minimal Residual Disease (MRD) and Immune Medicine. The MRD business focuses on the use of its sensitive, next-generation sequencing (NGS) assay to measure MRD in patients with hematologic malignancies. Its MRD business is comprised of its clonoSEQ clinical diagnostic test, offered to clinicians. The IM business focuses on the discovery and development of transformative immune-based therapies in the treatment of patients with cancer and autoimmune diseases.
ABCELLERA BIOLOGICS INC
AbCellera Biologics Inc is a biotechnology company that provides technology to discover and develop novel fully human monoclonal antibodies.
Baskets Featuring IMTX
Pharma's Private Equity Pivot: The Immunology Opportunity
Bristol Myers Squibb has partnered with Bain Capital to launch a new immunology-focused firm, highlighting a trend of pharma giants spinning out assets with private equity backing. This creates an investment opportunity in specialized biotech companies and the broader drug development ecosystem that supports them.
Published: July 29, 2025
Explore BasketGerman Stocks Soaring
Discover a carefully selected collection of German companies that have been dramatically outperforming their western counterparts. Our team of professional analysts has identified these standout stocks as Germany's economy shows promising signs of growth in 2025.
Published: May 15, 2025
Explore BasketWhy You’ll Want to Watch This Stock
Pipeline‑driven upside
Immatics’ valuation depends heavily on clinical trial results and regulatory readouts, which can create meaningful movement in either direction; outcomes are uncertain.
TCR technology focus
The company's T‑cell receptor approach targets tumour‑specific antigens that may expand treatment options, though technical and regulatory hurdles remain.
Partnerships and funding
Collaborations and capital support can accelerate development and de‑risk programmes, but clinical‑stage firms commonly require more funding, which can dilute investors.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
6% Interest on Cash
Earn 6% AER on uninvested cash with daily interest payments.
